Seattle, Washington (PRWEB) November 09, 2014
Dr. Hoering brings distinguished academic and scientific achievements, executive leadership and over 15 years of experience to the role. Dr. Hoering, currently the Chief Scientific Officer at CRAB, presently serves as the lead statistician for the SWOG Myeloma Committee and is an active member of the Myeloma Steering Committee for the National Clinical Trials Network. Dr. Hoering also serves as the Director of the Biostatistics Core for a SPORE grant funded through the Sarcoma Alliance for Research Through Collaboration, and is the Co-Director of the Biostatistics Core for a Program Project through the Myeloma Institute for Research and Therapy.
Dr. John Crowley, CRAB’s current CEO says, “Antje brings a unique and comprehensive background in applied and methodological research in biostatistics, encompassing areas such as the design and analysis of oncology clinical trials, as well as the analysis of a wide variety of correlative data. I have worked with Antje for 10 years at CRAB, and am proud to hand over the leadership reins to her.”
Dr. Antje Hoering comments, “I am honored and humbled to be taking over the reins from our founder, John Crowley. This is a very exciting time for oncology clinical trials and CRAB. There have been great advances in the treatment of cancer over the last few years and it is now more important than ever to definitively test the efficacy and tolerability of these treatments in soundly-designed clinical trials. CRAB offers an integrated, state-of-the-art infrastructure including sophisticated statistics, secure electronic data capture as well as experienced data management to lead such trials.”
Hoering will succeed John Crowley, CRAB’s founder and CEO since 1997, who will stay on to focus on research and project activities and will continue to serve as CRAB’s Chairman of the Board.
Dr. Hoering will be based at CRAB’s headquarters in Seattle, WA.
About Cancer Research And Biostatistics (CRAB)
CRAB is a non-profit organization whose mission is to help conquer cancer and other diseases through the application of biostatistical principles and innovative data management methods. CRAB provides a complete suite of cancer clinical trial services including the design of therapeutic and prevention trials, customized electronic data capture platforms, and data management and statistical services from clinical protocol design to final data analysis and presentation.
For more information, visit http://www.crab.org